🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans

Delma Caiati

Stock Analyst at Guggenheim

(1.54)
# 3,108
Out of 5,162 analysts
14
Total ratings
50%
Success rate
-0.9%
Average return

Stocks Rated by Delma Caiati

LB Pharmaceuticals
Nov 13, 2026
Reiterated: Buy
Price Target: $80
Current: $42.46
Upside: +88.41%
Rapport Therapeutics
Nov 4, 2026
Reiterated: Buy
Price Target: $70 → $66
Current: $25.85
Upside: +155.32%
Neurocrine Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $207 → $224
Current: $169.40
Upside: +32.23%
Xenon Pharmaceuticals
Oct 29, 2026
Reiterated: Buy
Price Target: $73
Current: $41.00
Upside: +78.07%
MapLight Therapeutics
Oct 5, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $7.07
Upside: -
Ovid Therapeutics
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.55
Upside: +174.51%